Alpha-galactosidase A precursor
Alpha-galactosidase A precursor Brand names, Alpha-galactosidase A precursor Analogs
Alpha-galactosidase A precursor Brand Names Mixture
- No information avaliable
Alpha-galactosidase A precursor Chemical_Formula
C2029H3080N544O587S27
Alpha-galactosidase A precursor RX_link
http://www.rxlist.com/cgi/generic3/fabrazyme.htm
Alpha-galactosidase A precursor fda sheet
Alpha-galactosidase A precursor msds (material safety sheet)
Alpha-galactosidase A precursor Synthesis Reference
No information avaliable
Alpha-galactosidase A precursor Molecular Weight
45351.6
Alpha-galactosidase A precursor Melting Point
No information avaliable
Alpha-galactosidase A precursor H2O Solubility
No information avaliable
Alpha-galactosidase A precursor State
Liquid
Alpha-galactosidase A precursor LogP
-0.307
Alpha-galactosidase A precursor Dosage Forms
Powder for solution
Alpha-galactosidase A precursor Indication
For treatment of Fabry's disease (alpha-galactosidase A deficiency)
Alpha-galactosidase A precursor Pharmacology
Used in the treatment of Fabry disease, an X-linked genetic disorder of glycosphingolipid metabolism. The disease is characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A, which leads to progressive accumulation of glycosphingolipids, predominantly GL-3, in many body tissues. Clinical manifestations of Fabry disease include renal failure, cardiomyopathy, and cerebrovascular accidents. Fabrazyme is intended to provide an exogenous source of alpha-galactosidase A and to limit the accumulation of these glycolipids in the tissues.
Alpha-galactosidase A precursor Absorption
No information avaliable
Alpha-galactosidase A precursor side effects and Toxicity
No information avaliable
Alpha-galactosidase A precursor Patient Information
BIOD00075.html
Alpha-galactosidase A precursor Organisms Affected
Humans and other mammals
